Perrigo and Cobrek file for generic Evoclin
Perrigo says that its partner Cobrek Pharmaceuticals, has filed an Abbreviated New Drug Application for clindamycin phosphate foam 1%, a generic version of fellow USA-based Stiefel's Evoclin Foam 1%, which it believes is the first to file an ANDA with a Paragraph IV certification against this drug.
Evoclin Foam 1% is a topical antibiotic indicated for the treatment of acne vulgaris, and had sales of about $44.0 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.
The ANDA for the generic product, which was filed prior to enactment of the First Quarter Program Supplemental Funding Act of 2008, was timely amended to contain a Paragraph IV Certification in accordance with the Q1 Act.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze